# Melior Discovery

> Melior Discovery is an Exton, Pennsylvania preclinical contract research organization that specializes in in vivo pharmacology and drug repositioning. Its proprietary theraTRACE platform runs a candidate compound through a large, multiplexed panel of validated animal disease models simultaneously, systematically surfacing new therapeutic uses for existing or shelved drugs. Founded in 2005 by Andrew Reaume and Michael Saporito, the company both partners with major pharmaceutical firms and builds its own drug pipeline through spinouts, and was named CRO of the Year by Life Sciences Review in 2024.

- **Founded:** 2005
- **Headquarters:** Exton, Pennsylvania, United States
- **Founders:** Andrew G. Reaume (Co-Founder, President & CEO), Michael Saporito (Co-Founder, VP of Research)
- **Team size:** ~24 employees
- **Products:** theraTRACE, immuno-theraTRACE, opioidTRACE, In vivo pharmacology / CRO services, Drug repositioning & indication discovery
- **Notable:** Named CRO of the Year 2024 by Life Sciences Review, cited for theraTRACE, immuno-theraTRACE and opioidTRACE platforms, Selected as a Top 20 CRO by Pharma Tech Outlook (2023), Established and validated 80+ (now 150+) animal disease models across ~14 therapeutic areas

## Products & services

- **theraTRACE** — A proprietary, multiplexed phenotypic screening platform that runs a single compound simultaneously through a large panel of validated in vivo disease models to systematically and rapidly identify previously unknown therapeutic applications.
- **immuno-theraTRACE** — An oncology- and immuno-oncology-focused extension of the theraTRACE platform for identifying new applications of candidates in cancer immunotherapy.
- **opioidTRACE** — An analgesic-focused screening platform for evaluating pain and opioid-related pharmacology in vivo.
- **In vivo pharmacology / CRO services** — Contract research services spanning 150+ validated rat and mouse disease models across roughly 14 therapeutic areas, including custom model development and replication of published literature models.
- **Drug repositioning & indication discovery** — End-to-end programs that take existing or discontinued compounds and identify and validate new indications, feeding both partner pipelines and Melior's own spinouts.

## Achievements

- Named CRO of the Year 2024 by Life Sciences Review, cited for theraTRACE, immuno-theraTRACE and opioidTRACE platforms
- Selected as a Top 20 CRO by Pharma Tech Outlook (2023)
- Established and validated 80+ (now 150+) animal disease models across ~14 therapeutic areas
- Discovered and advanced MLR-1023, a novel non-PPARgamma insulin sensitizer, from repositioning through two Phase 2 diabetes studies (~600 subjects, 80 clinical sites, two countries)
- Raised ~$15M in investment capital and completed ~$40M in partnering deals across the Melior companies
- Great Place to Work certified; AAALAC International accredited; DEA Schedule I-V licensed

## Latest updates

- **2024-03** — Recognized as CRO of the Year by Life Sciences Review, highlighting theraTRACE, immuno-theraTRACE and opioidTRACE.
- **2024-05** — Published work on the value of strategic partnerships in cancer therapy innovation, including glioma model work with Modifi Bio.
- **2023-06** — Named a Top 20 CRO by Pharma Tech Outlook.
- **2020-06** — Announced partnership with SFA Therapeutics on a grant directed at COVID-19.

## Links

- Website: https://meliordiscovery.com
- LinkedIn: http://www.linkedin.com/company/melior-discovery
- Twitter/X: https://twitter.com/melior_discover
- Facebook: https://facebook.com/Melior-Discovery-1397620873638652/

---

Profile page: https://yespress.io/melior-discovery
Published by YesPress — https://yespress.io
Last updated: 2026-08-03